Revenue Performance - Revenue for Q3 2024 was $533.3 million, an increase of 8.3% from $492.5 million in Q3 2023, with a backlog conversion rate of 18.2%[2] - Year-to-date revenue for 2024 was $1,572.5 million, reflecting a 13.3% increase from the prior year[7] - Full year 2024 revenue is forecasted to be between $2.090 billion and $2.130 billion, indicating growth of 10.8% to 12.9% over 2023[9] - Net revenue for the three months ended September 30, 2024, was $533,317,000, representing a 8.3% increase from $492,499,000 in the same period of 2023[19] Profitability Metrics - GAAP net income for Q3 2024 was $96.4 million, or $3.01 per diluted share, compared to $70.6 million, or $2.22 per diluted share in Q3 2023, with a net income margin of 18.1%[5] - Net income for the nine months ended September 30, 2024, was $287,368,000, up 40.4% from $204,512,000 in the same period of 2023[19] - Basic net income per share attributable to common shareholders for the three months ended September 30, 2024, was $3.11, compared to $2.30 for the same period in 2023, reflecting a 35.2% increase[19] - Full year 2024 GAAP net income is projected to be between $376.0 million and $388.0 million[9] Cash Flow and Liquidity - Cash and cash equivalents were $656.9 million as of September 30, 2024, with $149.1 million generated in cash flow from operating activities during Q3 2024[8] - Cash and cash equivalents rose significantly to $656,900,000 as of September 30, 2024, compared to $245,449,000 at the end of 2023, indicating a 167.5% increase[21] Backlog and Business Awards - Net new business awards in Q3 2024 were $533.7 million, a decrease of 12.7% from $611.5 million in Q3 2023, resulting in a net book-to-bill ratio of 1.00x[4] - Backlog as of September 30, 2024, increased by 8.8% to $2,927.4 million from $2,689.5 million in the prior year[4] Operating Expenses and EBITDA - EBITDA for Q3 2024 increased by 31.7% to $118.8 million, representing an EBITDA margin of 22.3%, compared to $90.2 million and 18.3% in Q3 2023[5] - EBITDA for the nine months ended September 30, 2024, was $346,672,000, compared to $266,663,000 for the same period in 2023, reflecting a 30.0% increase[26] Shareholder Equity and Repurchase Program - Total shareholders' equity rose to $881,439,000 as of September 30, 2024, compared to $558,950,000 at the end of 2023, indicating a 57.7% increase[22] - The company had $308.8 million remaining under its authorized share repurchase program as of September 30, 2024[8] Advanced Billings - Advanced billings increased to $670,939,000 as of September 30, 2024, from $559,860,000 at the end of 2023, showing a 19.8% growth[21]

Medpace (MEDP) closed the most recent trading day at $343.05, moving +1.57% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.9%. Meanwhile, the Dow gained 0.81%, and the Nasdaq, a tech-heavy index, added 1.22%. The provider of outsourced clinical development services's shares have seen a decrease of 2.78% over the last month, surpassing the Medical sector's loss of 4.05% and falling behind the S&P 500's gain of 3.15%. Market participants will be close ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ: MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MEDP. Investigation Details On September 25, 2025, Jefferies downgraded Medpace, citing perceived weaknesses in the Com ...

In the latest market close, Medpace (MEDP) reached $354.65, with a -0.57% movement compared to the previous day. This change lagged the S&P 500's 0.03% gain on the day. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.2%. The provider of outsourced clinical development services's stock has dropped by 9.01% in the past month, falling short of the Medical sector's gain of 2.67% and the S&P 500's gain of 1.54%. The upcoming earnings release of Medpace will ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Medpace (MEDP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Medpace currently has an average brokerage recommendation (ABR ...

Medpace (MEDP) closed the latest trading day at $339.38, indicating a +1.08% change from the previous session's end. This change lagged the S&P 500's 1.16% gain on the day. Elsewhere, the Dow gained 1.2%, while the tech-heavy Nasdaq added 1.16%. Shares of the provider of outsourced clinical development services have depreciated by 13.17% over the course of the past month, underperforming the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%. Analysts and investors alike will be keeping a close e ...

Core Insights - Medpace Holdings (NASDAQ:MEDP) stock has increased by 69% since the buy rating was issued in January 2023, confirming the initial investment thesis from July 2022 [5] - The company demonstrates strong profitability with a return on invested capital (ROIC) of over 33%, driven by 16% NOPAT margins and a capital turnover of approximately 2.4x [5][8] - Free cash flow (FCF) generation has been robust, ranging from $200 million to $500 million annually since FY'21, with minimal incremental capital employed [5][8] - The company has a solid backlog of approximately $2.9 billion, reflecting a year-over-year increase of 13.7% [10][12] - Management has revised FY24 sales guidance to between $2.125 billion and $2.175 billion, indicating a top-line growth of 13% to 15.3% year-over-year [8][12] Financial Performance - Q2 FY'24 revenues reached $28.1 million, marking a 14.6% year-over-year increase, with year-to-date sales totaling $1.04 billion, up 16.1% year-over-year [8][12] - EBITDA for Q2 is projected between $430 million and $460 million, reflecting a growth of 27% at the upper end, with earnings per share estimated at $11.93 [8][12] - The net new business awards decreased by 4.1% year-over-year to $551 million, with a net book-to-bill ratio of 1.04, indicating a healthy but slightly declining trend [9][12] Valuation and Growth Potential - The intrinsic value of MEDP is estimated to exceed $400 per share, supported by a compounding growth rate of 5% in intrinsic value and a potential reinvestment of 15% of cumulative NOPAT at 20-30% incremental returns [19][22] - The company has maintained a high ROIC, which is expected to attract higher EV/IC multiples, enhancing its market valuation [16][22] - Future projections indicate that economic earnings could reach approximately $287.34 million in FY'24, with a per-share value of $9.33 [25]

Core Viewpoint - Medpace Holdings, Inc. has faced significant stock price decline following disappointing second quarter 2024 financial results, raising concerns about potential violations of federal securities laws and unlawful business practices [2][1]. Financial Performance - On July 22, 2024, Medpace reported second quarter 2024 financial results that significantly missed market expectations [2]. - The company experienced disproportionately high cancellations in June 2024, attributed to factors such as reprioritization, impaired sponsor liquidity, and a large pharmaceutical acquisition that led to work being shifted to a preferred provider [2]. Stock Market Reaction - Following the earnings announcement, Medpace's stock price dropped by $79.88, or 18.3%, closing at $357.30 per share on July 23, 2024, resulting in losses for investors [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Medpace on behalf of its stockholders regarding possible violations of federal securities laws and other unlawful business practices [1].

Core Insights - Medpace Holdings, Inc. is under investigation by Hagens Berman due to concerns over its financial performance and public statements, particularly regarding its growth assurances that were contradicted by its latest earnings report [1][3] Financial Performance - On July 23, Medpace reported a significantly lower-than-expected book-to-bill ratio for Q2, attributed to "elevated project cancellations," which has raised concerns among investors and analysts [2] - The unexpected results led to an 18% drop in Medpace's share price on the announcement day, described by William Blair analyst Max Smock as "shocking" and "alarming" due to the stark discrepancy from prior guidance [3] Investigation Details - Hagens Berman is investigating whether Medpace misled investors regarding the health of its business, with a focus on potential violations of U.S. securities laws [4] - The firm is encouraging individuals with knowledge of the situation or who have suffered losses to come forward and assist in the investigation [4]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Medpace (MEDP) being highlighted as a strong candidate due to its favorable growth metrics and earnings estimates [1][2]. Earnings Growth - Medpace has a historical EPS growth rate of 32.2%, with projected EPS growth of 27.1% for the current year, significantly outperforming the industry average of 15.7% [3]. - The Zacks Consensus Estimate for Medpace's current year earnings has increased by 0.4% over the past month, indicating positive earnings estimate revisions [5][10]. Cash Flow Growth - Medpace's year-over-year cash flow growth stands at 15.5%, which is notably higher than the industry average of -14.2% [4]. - The company's annualized cash flow growth rate over the past 3-5 years is 19.4%, compared to the industry average of 13.4% [18]. Growth Score and Rankings - Medpace has achieved a Zacks Rank of 2 (Buy) and a Growth Score of A, reflecting its strong growth characteristics and favorable earnings estimate revisions [10][11]. - Stocks with a combination of a Growth Score of A or B and a Zacks Rank of 1 (Strong Buy) or 2 (Buy) have historically outperformed the market [11]. Investment Outlook - The combination of strong earnings and cash flow growth positions Medpace well for potential outperformance, making it an attractive option for growth investors [20].